Orthox is a self-described leading medical device company that develops treatments for injuries to cartilage and other hard-to-heal human tissues.

Orthox

Founded to commercialise technology developed at Oxford University, Orthox aims to revolutionise the way cartilage injuries are treated.  Trauma and erosion of the smooth, stiff cartilage in our joints leads to Osteoarthritis (OA) a debilitating disease, which affects over 300 million patients globally and costs the US economy alone over $128 billion each year. 

Current therapies to repair damaged cartilage focus either on tissue regeneration or on functional replacement; Orthox’s exceptionally strong, resilient, regenerative hydrogel technology, FibroFix™  achieves both these goals, offering a unique solution for the millions of patients suffering from damage to their joints.

Initially targeting the knee, Orthox has developed a compelling set of data on lead product FibroFix™ Cartilage which has secured major awards from multiple funding bodies and is currently undergoing evaluation through the FFLEX clinical study being run at major hospitals across Europe. FibroFix™ technology will then be rolled out to treat damaged cartilage in other joints while pipeline products beyond orthopaedics in which the application of great strength and tissue regeneration are key will also be developed.

Pipeline expansion is valuable as growth in the annual global biomaterials market will exceed $250 billion by 2025. Orthopaedic biomaterials will form the largest proportion of this and natural biomaterials, like FibroFix™, will be the fastest growing market segment.

Orthox: Reducing Pain, Increasing Mobility, Regenerating Strength™.

EIT Health

National Institute for Health Research

Innovate UK

EASME - EU Executive Agency for SMEs

Additio Investment Group

Oxford Investment Consultants LLP

Parkwalk Advisors

Perivoli Innovations

AtmosClear Investments

ORTHOX LIMITED

We are delighted to announce that we have received a “Letter of No Objection” from the UK’s MHRA, enabling the start of our “FFLEX Study” (derived from the “FibroFix cartiLage repair Experience”). This important clinical trial will assess the safety and performance of our FibroFix™ Cartilage implant and accessory surgical instrumentation in the knee joints of patients suffering with cartilage injuries. 
Patient recruitment is expected to open this month at our lead clinical site, Southmead Hospital, Bristol, UK.
We have also received grant of key patents in the US, China, the UK, Germany, and France providing long term protection for our FibroFix™ implant platform in these major global economies.
 #mhra #patents #cartilage #knee #medtech

industry_trends_dossier

news_impact_assignment_basic

key_people

company_dossier

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

network

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

events

strategic_challenges

network_mapping

industry_trends

transactions_dossier

strategic_challenges_dossier

network_onboarding

company_summary

regulatory_analysis

industry_analysis

swot_dossier

competition_analysis

financial_legal_advisories

merger_acquisitions

swot_analysis

financial_analysis

news_advanced

purchaser_profile

news_impact_assignment_advanced

signals

news_processing_advanced

financial_statements

private_financials

funding_rounds_analysis

company_structure

crunchbase_trigger

crunchbase_profile

li_profile

translate_crunchbase_fundingrounds

peers

news_basic

valuation

customer_profile

industry trends dossier	dataroom
company dossier	dataroom
network	dataroom
network mapping	dataroom
transactions dossier	dataroom
network onboarding	dataroom
news impact assignment basic	general
public peers	general	Aug 31, 2024 4:03 PM	3b0fcfbd
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
news advanced	general
news impact assignment advanced	general
signals	general
news processing advanced	general
crunchbase trigger	general
crunchbase profile	general
li profile	general	Aug 31, 2024 4:03 PM	8739afbe
translate crunchbase fundingrounds	general
peers	general	Aug 31, 2024 4:03 PM	c762fb99
news basic	general	Aug 31, 2024 4:03 PM	b2f29374
events	markdown
bundesanzeiger	filings
regulatory analysis	company_analysis
industry analysis	company_analysis
competition analysis	company_analysis
financial legal advisories	company_analysis
merger acquisitions	company_analysis
swot analysis	company_analysis
financial analysis	company_analysis
funding rounds analysis	company_analysis
company structure	company_analysis
purchaser profile	merger_acquisitions
private financials	financials
customer profile	customers

ORTH

COM:ORTHOX

Orthox